Michael Kongnyuy1, Shahidul Islam2, Alfred K Mbah3, Daniel M Halpern4, Glenn T Werneburg5, Kaitlin E Kosinski4, Connie Chen5, David J Habibian6, Jeffrey T Schiff4, Anthony T Corcoran4, Aaron E Katz4. 1. Department of Urology, NYU-Winthrop Hospital, 1300 Franklin Ave, Garden City, Mineola, NY, 11530, USA. speeditomike@gmail.com. 2. Department of Biostatistics, NYU-Winthrop Hospital, Mineola, NY, USA. 3. University of South Florida College of Public Health, Tampa, FL, USA. 4. Department of Urology, NYU-Winthrop Hospital, 1300 Franklin Ave, Garden City, Mineola, NY, 11530, USA. 5. Stony Brook University School of Medicine, Stony Brook, NY, USA. 6. St George's University School of Medicine, True Blue, Grenada.
Abstract
PURPOSE: We aim to evaluate prostate-specific antigen (PSA) trends in post-primary focal cryotherapy (PFC) patients. MATERIALS AND METHODS: This was an institutional review board-approved retrospective study of PFC patients from 2010 to 2015. Patients with at least one post-PFC PSA were included in the study. Biochemical recurrence (BCR) was determined using the Phoenix criteria. PSA bounce was also assessed. We analyzed rates of change of PSA over time of post-PFC between BCR and no BCR groups. PSA-derived variables were analyzed as potential predictors of BCR. RESULTS: A total of 104 PFC patients were included in our analysis. Median (range) age and follow-up time were 66 (48-82) years and 19 (6.3-38.6) months, respectively. Four (3.8%) patients experienced PSA bounce. The median percent drop in first post-PFC PSA of 80.0% was not associated with BCR (p = 0.256) and may indicate elimination of the index lesion. The rate of increase of PSA in BCR patients was significantly higher compared to patients who did not recur (median PSA velocity (PSAV): 0.15 vs 0.04 ng/ml/month, p = 0.001). Similar to PSAV (HR 9.570, 95% CI 3.725-24.592, p < 0.0001), PSA nadir ≥ 2 ng/ml [HR (hazard ratio) 1.251, 95% CI 1.100-1.422, p = 0.001] was independently associated with BCR. CONCLUSION: A significant drop in post-PFC PSA may indicate elimination of the index lesion. Patients who are likely to recur biochemically have a significantly higher PSAV compared to those who do not recur. Nadir PSA of less than 2 ng/ml may be considered the new normal PSA in focal cryotherapy (hemiablation) follow-up.
PURPOSE: We aim to evaluate prostate-specific antigen (PSA) trends in post-primary focal cryotherapy (PFC) patients. MATERIALS AND METHODS: This was an institutional review board-approved retrospective study of PFC patients from 2010 to 2015. Patients with at least one post-PFC PSA were included in the study. Biochemical recurrence (BCR) was determined using the Phoenix criteria. PSA bounce was also assessed. We analyzed rates of change of PSA over time of post-PFC between BCR and no BCR groups. PSA-derived variables were analyzed as potential predictors of BCR. RESULTS: A total of 104 PFC patients were included in our analysis. Median (range) age and follow-up time were 66 (48-82) years and 19 (6.3-38.6) months, respectively. Four (3.8%) patients experienced PSA bounce. The median percent drop in first post-PFC PSA of 80.0% was not associated with BCR (p = 0.256) and may indicate elimination of the index lesion. The rate of increase of PSA in BCR patients was significantly higher compared to patients who did not recur (median PSA velocity (PSAV): 0.15 vs 0.04 ng/ml/month, p = 0.001). Similar to PSAV (HR 9.570, 95% CI 3.725-24.592, p < 0.0001), PSA nadir ≥ 2 ng/ml [HR (hazard ratio) 1.251, 95% CI 1.100-1.422, p = 0.001] was independently associated with BCR. CONCLUSION: A significant drop in post-PFC PSA may indicate elimination of the index lesion. Patients who are likely to recur biochemically have a significantly higher PSAV compared to those who do not recur. Nadir PSA of less than 2 ng/ml may be considered the new normal PSA in focal cryotherapy (hemiablation) follow-up.
Authors: D Nathan Kim; Christopher Straka; L Chinsoo Cho; Yair Lotan; Jingsheng Yan; Brian Kavanagh; David Raben; Susan Cooley; Jeffrey Brindle; Xian Jin Xie; David Pistenmaa; Robert Timmerman Journal: Pract Radiat Oncol Date: 2016-06-24
Authors: Duke Bahn; Andre Luis de Castro Abreu; Inderbir S Gill; Andrew J Hung; Paul Silverman; Mitchell E Gross; Gary Lieskovsky; Osamu Ukimura Journal: Eur Urol Date: 2012-03-21 Impact factor: 20.096
Authors: Amir Toussi; Suzanne B Stewart-Merrill; Stephen A Boorjian; Sarah P Psutka; R Houston Thompson; Igor Frank; Matthew K Tollefson; Matthew T Gettman; Rachel E Carlson; Laureano J Rangel; R Jeffrey Karnes Journal: J Urol Date: 2015-12-23 Impact factor: 7.450
Authors: Michael Kongnyuy; Michael J Lipsky; Shahidul Islam; Dennis J Robins; Shaun Hager; Daniel M Halpern; Kaitlin E Kosinski; Jeffrey T Schiff; Anthony T Corcoran; Sven Wenske; Aaron E Katz Journal: Urol Oncol Date: 2017-04-11 Impact factor: 3.498
Authors: R van Velthoven; F Aoun; Q Marcelis; S Albisinni; M Zanaty; M Lemort; A Peltier; K Limani Journal: Prostate Cancer Prostatic Dis Date: 2015-11-24 Impact factor: 5.554
Authors: A W Partin; J D Pearson; P K Landis; H B Carter; C R Pound; J Q Clemens; J I Epstein; P C Walsh Journal: Urology Date: 1994-05 Impact factor: 2.649
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Rafael R Tourinho-Barbosa; Lucas Teixeira Batista; Xavier Cathelineau; Javier Sanchez-Macias; Rafael Sanchez-Salas Journal: Turk J Urol Date: 2020-10-09
Authors: Rafael R Tourinho-Barbosa; Bradford J Wood; Andre Luis Abreu; Bruno Nahar; Toshitaka Shin; Selcuk Guven; Thomas J Polascik Journal: World J Urol Date: 2020-05-22 Impact factor: 4.226
Authors: Masakatsu Oishi; Inderbir S Gill; Alessandro Tafuri; Aliasger Shakir; Giovanni E Cacciamani; Tsuyoshi Iwata; Atsuko Iwata; Akbar Ashrafi; Daniel Park; Jie Cai; Mihir Desai; Osamu Ukimura; Duke K Bahn; Andre Luis Abreu Journal: J Urol Date: 2019-07-26 Impact factor: 7.600
Authors: Antony Pellegrino; Giuseppe O Cirulli; Elio Mazzone; Francesco Barletta; Simone Scuderi; Mario de Angelis; Giuseppe Rosiello; Giorgio Gandaglia; Francesco Montorsi; Alberto Briganti; Armando Stabile Journal: Ann Transl Med Date: 2022-07